|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
KR20230030022A
(ko)
|
2014-11-13 |
2023-03-03 |
더 존스 홉킨스 유니버시티 |
관문 차단 및 미소부수체 불안정성
|
|
MA40737A
(fr)
*
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
US20180133327A1
(en)
*
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
US20190099475A1
(en)
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
BR112017022845A2
(pt)
*
|
2015-04-23 |
2018-07-17 |
Nantomics, Llc |
neoepítopos de câncer
|
|
EA201792501A1
(ru)
|
2015-05-13 |
2018-10-31 |
Эйдженус Инк. |
Вакцины для лечения и профилактики рака
|
|
GB201516047D0
(en)
*
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
EP3362929B1
(en)
*
|
2015-10-12 |
2020-08-12 |
Nantomics, LLC |
Viral neoepitopes and uses thereof
|
|
CA3003251A1
(en)
*
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
|
|
MX2018004544A
(es)
*
|
2015-10-12 |
2018-11-09 |
Nantomics Llc |
Composiciones y métodos para los neoepítopos de cáncer viral.
|
|
EP3365000B1
(en)
|
2015-10-23 |
2020-06-10 |
Novartis AG |
Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
ES2970865T3
(es)
|
2015-12-16 |
2024-05-31 |
Gritstone Bio Inc |
Identificación, fabricación y uso de neoantígenos
|
|
EP3400005A1
(en)
*
|
2016-01-08 |
2018-11-14 |
Vaccibody AS |
Neoepitope rna cancer vaccine
|
|
WO2017143092A1
(en)
|
2016-02-19 |
2017-08-24 |
Nant Holdings Ip, Llc |
Methods of immunogenic modulation
|
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
CA3015913A1
(en)
*
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
JP6710004B2
(ja)
*
|
2016-03-15 |
2020-06-17 |
Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 |
免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
|
|
PL3429618T3
(pl)
*
|
2016-03-16 |
2024-07-01 |
Amal Therapeutics Sa |
Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
|
|
WO2017214575A1
(en)
*
|
2016-06-10 |
2017-12-14 |
Io Therapeutics, Inc. |
Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
|
|
US20190247435A1
(en)
*
|
2016-06-29 |
2019-08-15 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
HUE067838T2
(hu)
|
2016-09-21 |
2024-11-28 |
Amal Therapeutics Sa |
Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
|
|
EP3516081A4
(en)
*
|
2016-09-23 |
2020-07-29 |
Memorial Sloan Kettering Cancer Center |
DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
|
|
CA3038712A1
(en)
*
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2018102613A2
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
WO2018112449A2
(en)
|
2016-12-16 |
2018-06-21 |
Nant Holdings Ip, Llc |
Live cell imaging systems and methods to validate triggering of immune response
|
|
WO2018132753A1
(en)
*
|
2017-01-13 |
2018-07-19 |
Nantbio, Inc. |
Validation of neoepitope-based treatment
|
|
WO2018136664A1
(en)
|
2017-01-18 |
2018-07-26 |
Ichan School Of Medicine At Mount Sinai |
Neoantigens and uses thereof for treating cancer
|
|
WO2018146128A1
(en)
*
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
SG11201908129PA
(en)
*
|
2017-03-17 |
2019-10-30 |
Nantomics Llc |
LIQUID BIOPSY FOR cfRNA
|
|
EP3601355A1
(en)
*
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3933408A1
(en)
|
2017-05-30 |
2022-01-05 |
Nant Holdings IP LLC |
Circulating tumor cell enrichment using neoepitopes
|
|
JP2020522479A
(ja)
|
2017-06-02 |
2020-07-30 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ |
個別化された癌ワクチンを作製する方法
|
|
GB202209539D0
(en)
*
|
2017-06-13 |
2022-08-10 |
Bostongene Corp |
Systems and methods for identifying cancer treatments from normalized biomarker scores
|
|
GB201710815D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Francis Crick Inst Ltd |
Method
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
AU2018336785B2
(en)
|
2017-09-20 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
|
|
EP3688165A4
(en)
|
2017-09-25 |
2021-09-29 |
Nant Holdings IP, LLC |
VALIDATION OF THE PRESENTATION OF NEOEPITOPES
|
|
CN117987553A
(zh)
*
|
2017-09-25 |
2024-05-07 |
纪念斯隆凯特琳癌症中心 |
肿瘤突变负荷和检查点免疫疗法
|
|
EP4576103A3
(en)
|
2017-10-10 |
2025-08-27 |
Gritstone bio, Inc. |
Neoantigen identification using hotspots
|
|
CN111247169A
(zh)
|
2017-10-15 |
2020-06-05 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
WO2019090156A1
(en)
|
2017-11-03 |
2019-05-09 |
Guardant Health, Inc. |
Normalizing tumor mutation burden
|
|
JP2021503077A
(ja)
*
|
2017-11-09 |
2021-02-04 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
細胞外小胞タンパク質、ならびに癌診断、療法に対する応答予測、および治療をするためのそれらの使用
|
|
CN111630602A
(zh)
|
2017-11-22 |
2020-09-04 |
磨石肿瘤生物技术公司 |
减少新抗原的接合表位呈递
|
|
WO2019109086A1
(en)
|
2017-12-01 |
2019-06-06 |
Illumina, Inc. |
Methods and systems for determining somatic mutation clonality
|
|
CN108009400B
(zh)
*
|
2018-01-11 |
2018-07-06 |
至本医疗科技（上海）有限公司 |
全基因组肿瘤突变负荷预测方法、设备以及存储介质
|
|
US11414698B2
(en)
*
|
2018-03-22 |
2022-08-16 |
Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi |
Method of quantifying mutant allele burden of target gene
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
WO2020023420A2
(en)
|
2018-07-23 |
2020-01-30 |
Guardant Health, Inc. |
Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
|
|
CN121354685A
(zh)
|
2018-08-31 |
2026-01-16 |
夸登特健康公司 |
无细胞dna中的微卫星不稳定性检测
|
|
CN109371005B
(zh)
*
|
2018-11-12 |
2022-09-30 |
上海市东方医院（同济大学附属东方医院） |
一种hla-0201限制性padi4表位多肽及其应用
|
|
US20200190598A1
(en)
*
|
2018-12-12 |
2020-06-18 |
Medimmune, Llc |
Blood-based tumor mutation burden predicts overall survival in nsclc
|
|
CN113692449A
(zh)
*
|
2018-12-21 |
2021-11-23 |
新加坡科技研究局 |
预测免疫检查点抑制疗法益处的方法
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
US12031181B2
(en)
|
2019-04-05 |
2024-07-09 |
Illumina, Inc. |
Quantitative score of HLA diversity
|
|
EP3977136A4
(en)
*
|
2019-05-24 |
2023-05-10 |
Edifice Health, Inc. |
PRECISION DRUGS FOR CANCER IMMUNOTHERAPY
|
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
NL2024107B1
(en)
*
|
2019-10-26 |
2021-07-19 |
Vitroscan B V |
Compositions for Patient Specific Immunotherapy
|
|
CN111088349B
(zh)
*
|
2020-02-14 |
2023-04-28 |
深圳市宝安区妇幼保健院 |
Kir3dl1基因分型引物组及其应用
|
|
EP4127243B1
(en)
*
|
2020-03-23 |
2023-11-22 |
Koninklijke Philips N.V. |
Prediction of radiotherapy response for prostate cancer subject based on immune checkpoint genes
|
|
GB202007099D0
(en)
|
2020-05-14 |
2020-07-01 |
Kymab Ltd |
Tumour biomarkers for immunotherapy
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4000596A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
EP4000595A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
US20240192195A1
(en)
*
|
2021-04-10 |
2024-06-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
A multiomic approach to modeling of gene regulatory networks in multiple myeloma
|
|
WO2023025404A1
(en)
|
2021-08-24 |
2023-03-02 |
BioNTech SE |
In vitro transcription technologies
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
WO2024216165A1
(en)
|
2023-04-12 |
2024-10-17 |
Icahn School Of Medicine At Mount Sinai |
Computational methods for selecting personalized neoantigen vaccines
|